Articles tagged with Breast Cancer
Researchers found that changes in breast density over time can predict a woman's risk of breast cancer, with higher densities linked to greater risks. Meanwhile, targeting prostate-specific proteins may lead to effective treatments for prostate cancer and other diseases, leaving non-prostate cells unharmed.
A novel detection procedure using nanotechnology and high-temperature superconductors enables surgeons to accurately locate the sentinel lymph node for breast cancer. The ultrasensitive magnetic probe detects minuscule magnetic fields, allowing for more effective staging and treatment of breast cancer.
Women treated with radiation for breast cancer between 1970 and 1986 have an increased risk of heart attack, angina, and congestive heart failure compared to the general female population. The study also found that smoking had a significant effect on heart disease risk in irradiated patients.
Mothers with breast cancer who experience depression may see their children's anxiety levels rise, particularly regarding family-related concerns. The study suggests that healthcare providers should look for signs of depression in patients to improve the mental well-being of families affected by breast cancer.
Researchers have successfully targeted the blood vessels that feed tumors, providing a new approach to treating cancer. The study used an antibody called J591 that selectively targets prostate-specific membrane antigen (PSMA) on tumors and not healthy tissues.
A team of researchers from Universitat Autonoma de Barcelona has identified the mechanism by which cancer cells resist chemotherapy. By understanding this pathway, scientists can develop strategies to make tumours more vulnerable to certain drugs, leading to improved treatment outcomes for patients with cancer.
A study found that pharmaceutical industry-sponsored breast cancer trials are more likely to report positive results than non-sponsored studies. These trials also tend to use single-arm designs, targeting patients with advanced disease, which may not answer questions about optimal treatment outcomes.
A study of 110,599 women found that long-term strenuous physical activity reduced the risk of invasive and in situ breast cancer by 20% and 31%, respectively. Moderate physical activity did not show a significant impact on breast cancer risk.
A recent USC-led study suggests that long-term recreational physical activity plays a protective role against invasive and in situ breast cancer. Women exercising for five or more hours per week experienced a greater decrease in risk of breast cancer compared to less active women.
Researchers found that Gab-2 is essential for breast cancer metastasis but not initial tumor growth. The study suggests a novel mechanism for breast cancer metastasis and identifies Gab-2 as a possible new target for therapies.
New research suggests that surgery-induced angiogenesis may contribute to the racial disparity in breast cancer mortality. In pre-menopausal women, this process can encourage tumor growth, leading to poorer outcomes. The study found a mean age of 43 for diagnosis in Nigerian women compared to 64 in the UK.
Researchers at Georgetown University Medical Center have isolated a protein, caveolin-1, that enhances cell death in response to Taxol chemotherapy in breast cancer cells. The protein needs to be phosphorylated to work, and its expression level can vary depending on the type of breast cancer.
Researchers found that African American women are diagnosed with breast cancer at an average age of 46, compared to 57 for white women. The study proposes that the excess mortality occurs partly because black women are more likely to develop breast cancer before menopause, when surgery may pose a higher risk of stimulating cancer growth.
Researchers used gene chips to profile tumors before treatment and found markers that identified breast cancer subtypes resistant to Herceptin. They discovered that IGF-1R expression was associated with a lower response rate, and that resistant tumors continued to over-express the HER2 growth factor protein.
Two randomized clinical trials found tamoxifen reduces ER-positive breast cancer risk by 27% and 39%. Long-term benefits persist even after stopping tamoxifen use, with reduced side effects.
A new screening protocol has been identified that can detect Lynch syndrome, a disorder that increases the risk of developing colorectal cancer at a young age. The screening procedure detected mutations in 69 patients and identified at least 57 HNPCC patients who would not have been screened under current testing practices.
Researchers have developed a new genomic microarray test that accurately identifies the ER and HER-2 status of breast tumors, which can inform personalized treatment planning. The test showed 90% accuracy for both receptors, comparable to existing pathology tests.
A novel drug sequence combining tamoxifen and exemestane has been shown to improve breast cancer survival rates in postmenopausal women by 17%, according to a new study. The treatment sequence was found to be safe and well-tolerated, offering hope for improved treatment options for patients worldwide.
A new analysis confirms the benefit of switching treatment from tamoxifen to an aromatase inhibitor on disease-free survival, with a modest improvement in overall survival for oestrogen-receptor-positive patients. The findings suggest that molecular markers may predict which patients benefit from endocrine treatment strategy.
Emerging research in breast cancer management includes advanced imaging technologies like 3D mammography and MRI, as well as novel vaccines that stimulate the immune system to attack tumors. This new approach aims to alter current screening and treatment paradigms, improving patient care.
Researchers at the University of Pennsylvania School of Medicine have developed a new model for discovering and evaluating anti-HIV drugs using a mouse protein called APOBEC3. The study found that APOBEC3 inhibits the infection and spread of a mouse tumor virus, providing a potential test system for evaluating human APOBEC3-based drugs.
A recent study published in Nature found that a genetic defect in PALB2 elevates the risk of both breast and prostate cancer. The mutation was discovered in Finnish breast cancer families and was also identified in patients with prostate cancer, suggesting its potential role as a susceptibility gene for heritable cancer.
Researchers discover PALB2 gene linked to increased breast cancer risk due to mutations, also found in prostate and colorectal cancers. The mutation causes impaired DNA repair leading to runaway cell growth.
Researchers found that SPECT/CT imaging enhances sentinel node identification in overweight patients with breast cancer. The study suggests this improved technique can reduce the need for unnecessary surgery and improve treatment outcomes.
A new report by the European Society for Medical Oncology warns that Europe's aging population is driving a major increase in cancer cases and deaths. The report estimates that there were 3.2 million new cancer cases diagnosed in 2006, with lung cancer remaining the leading cause of death.
A study published in the Journal of the National Cancer Institute found that women with breast cancer who received growth factors during chemotherapy had a higher risk of developing leukemia or myelodysplastic syndrome. The absolute risk is small, but it should be considered when making treatment decisions.
New studies using meta-analysis found a significant link between high vitamin D levels and reduced risk of breast and colorectal cancers. Individuals with the highest blood levels of 25-hydroxyvitamin D had the lowest risk of these cancers, with potential protective effects achievable through diet, supplements, or sunlight exposure.
Researchers used toll-like receptor agonists to stimulate an immune response against breast cancer tumors, preventing spontaneous growth and slowing tumor development. The vaccine was most effective when given prior to tumor appearance, extending survival but not curing the disease.
A new study from the University of Missouri-Columbia reveals that spirituality positively affects African-American women's willingness to talk about breast cancer and engage in preventative measures. For Caucasian women, spiritual locus of control plays no significant role in paying attention to breast cancer information.
The NHLBI has awarded 12 new contracts to the Women's Health Initiative (WHI) to investigate genetic and biological markers of common diseases in postmenopausal women. The studies will help explain hormone therapy findings and explore associations between physical activity, obesity, and inflammation with cardiovascular disease risk.
Men diagnosed with breast cancer are at a significantly high risk of developing a second primary cancer, particularly those of the breast, stomach, and skin. The researchers recommend closer monitoring and screening for these men to reduce the risk of second cancer.
Researchers found that radiation therapy after lumpectomy and tamoxifen treatment significantly reduced the risk of cancer recurrence and new tumors in older women with early breast cancer. The study's findings support providing high-quality care to all patients, regardless of age.
Researchers found that radiation therapy significantly reduced breast cancer recurrence and tumor development in older women with early-stage disease. The study, published in CANCER journal, recommends standard therapy for women of all ages and comorbidities, including mastectomy or breast conserving surgery with radiation.
A recent study found that nearly a quarter of women treated with tamoxifen for breast cancer stop taking the medication within one year, leading to concerns about treatment efficacy. The study also revealed that over one-third of women have ceased tamoxifen treatment after three and a half years.
A University of Michigan study found that women who took control of choosing their breast cancer surgeon were more likely to be treated by high-volume surgeons and at accredited cancer centers. Women with higher education and incomes were also more likely to select their surgeon based on reputation.
Obese and less educated women with breast cancer are more likely to receive reduced chemotherapy doses, threatening their survival. Research shows that doctors often reduce doses for these patients without solid medical basis, highlighting treatment disparities in cancer care.
A new study found that breast cancer patients with lower household income and less education are more likely to receive reduced doses of chemotherapy. Severely obese women were four times as likely to receive a reduced dose, while those with less than a high school education were three times as likely.
A recent study identified common flaws in oncology microarray studies, including inadequate methods to account for false-positive findings. Researchers provide guidelines to improve the quality of analysis and reporting of such studies, aiming to validate scientific findings through replication.
Researchers have found a selective marker in nestin that could lead to earlier detection and better treatment of basal epithelial breast tumors, a highly aggressive form of breast cancer. High levels of nestin were detected in 14 out of 16 tumor samples examined.
Researchers have discovered a potential new treatment for breast cancer by inhibiting the protease enzyme TACE, which is strongly present in aggressive forms of the disease. Inhibition of TACE blocks shedding of growth factor proteins, resulting in inhibition of cell division and reversion of malignant characteristics.
Researchers found DNA methylation in normal-appearing areas of the breast near tumors, suggesting a potential marker for early cancer detection. Abnormal methylation levels were also identified in three other genes, which may help estimate a woman's risk of cancer recurrence.
Researchers found that galectin-3 breaks down protective shield MUC1, allowing cancer cells to attach to blood vessel wall and form tumours at secondary sites. The study has significant implications for future drug developments for cancer treatment.
Researchers developed nanoparticles that home in on tumors by mimicking the clotting action of platelets, blocking up to 20% of tumor blood vessels. This system enables self-amplification of tumor targeting, leading to enhanced imaging and therapeutic delivery.
Drezek's research focuses on developing high-resolution in situ imaging of the molecular hallmarks of breast cancer, enabling doctors to detect biomarkers without tissue removal. The grant will be used to develop microendoscope and needle-compatible fiber optic systems for various diagnostic and therapeutic applications.
Giving women with HER2-receptor positive breast cancer Herceptin for one year after standard chemotherapy improves their survival. The study found a significant overall survival benefit in the drug group compared to the control group.
A new study by the University of Wisconsin-Madison found that breast cancer patients who pray in online support groups experience lower levels of negative emotions and higher self-efficacy. The study analyzed message transcripts from 97 patients and discovered a positive correlation between prayer and improved mental well-being.
Recent research suggests that regular statin use is not linked to lower colorectal cancer risk, while folate intake does not appear to impact breast cancer risk. However, monitoring of thyroid function may be necessary for patients taking the medication sunitinib, which can cause fatigue and hypothyroidism.
Researchers demonstrate that a combination of epigenetic drugs can reactivate the expression of over 1,000 genes in primary tumours of breast cancer patients. These reactivated genes play crucial roles in cell proliferation, differentiation, and immune recognition, suggesting increased anti-tumour effects.
A study found that viewing prior mammograms alongside current mammograms significantly improves radiologist performance and reduces unnecessary recalls. The use of prior mammograms recorded on film in comparison with digital mammograms poses a challenge, but limiting their availability may balance medical benefits with effort.
The GeneSearch Breast Lymph Node assay has been shown to have higher sensitivity and specificity in detecting breast cancer metastases compared to traditional intra-operative tests. The test's accuracy enables surgeons to make more informed treatment decisions and potentially reduce the need for second surgeries.
Researchers found that breast cancer in men is rare and can often be detected on physical examination. In most cases, a mammogram is not necessary for confirming gynecomastia diagnosis.
A randomized, phase III trial found that reducing dietary fat intake to 15% of total calories may prolong relapse-free survival in women with early-stage breast cancer. The study reported a 24% lower risk of relapse in the intervention group compared to the control group.
Researchers at Mayo Clinic have developed a new gamma camera technique that can detect breast tumors as tiny as one-fifth of an inch in diameter with 88% accuracy. The device is sensitive enough to identify small cancers that were not found by mammography, and may be more comfortable for women due to less pressure needed during imaging.
A new study demonstrates the effectiveness of Pfizer's Aromasin for early breast cancer treatment, with improved relapse-free survival and disease-free survival rates. The B-33 trial found that Aromasin was well-tolerated and showed a significant improvement in patients who received it after five years of tamoxifen.
A new report by Breast Cancer Action analyzes 612 women's responses to an online survey, finding nearly all reported side effects and 30% discontinued use due to intolerable side effects. The most common side effects included hot flashes, bone pain, and insomnia.
Scientists have discovered two protein biomarkers associated with breast cancer spread, which could help predict patient outcomes and guide treatment decisions. The study found that overexpression of one protein and underexpression of another were highly accurate in identifying patients at risk of metastasis.
Researchers developed genomic tests to predict breast cancer response to chemotherapy and hormonal therapy, with promising results in clinical trials. The tests showed high accuracy in predicting treatment response and patient outcomes, offering new hope for personalized treatment planning.
A Phase II trial found that 86% of patients with inflammatory breast cancer responded to lapatinib-chemotherapy, offering new hope for treatment. The study also showed that 25-30% of patients responded within two weeks of treatment alone.
A Phase III study found that combining Herceptin with chemotherapy significantly improves disease-free survival in women with early stage breast cancer and reduces the risk of heart damage. The study showed a five-fold decrease in significant heart toxicities compared to those who received Adriamycin.
A new analysis suggests that the decline in breast cancer incidence between 2002 and 2003 was largely due to the reduction of hormone replacement therapy (HRT) use. The study found a 7% relative decline in breast cancer cases, with an absolute decline of about 14,000 fewer women diagnosed in 2003 compared to 2002.